From 78 items, 1 important content pieces were selected

Technology News

  1. AI in Drug Discovery: Assessing Real Progress Versus Hype ⭐️ 7.0/10

Technology News

AI in Drug Discovery: Assessing Real Progress Versus Hype ⭐️ 7.0/10

This item discusses a Derek Lowe blog post on Science.org responding to a Nature perspective piece that critically assesses AI's actual contribution to drug discovery. The core argument is that AI has largely delivered incremental productivity gains, such as speeding up existing workflows, rather than transformative breakthroughs that fundamentally change how drugs are discovered. The Nature piece reportedly argues that the field must shift from modeling readily available data, which is unlikely to move the needle, toward generating new, substantial data even when that is harder and more expensive. This reframes the AI-in-science conversation as less about clever algorithms and more about the willingness of researchers and companies to invest in costly experimental data generation that AI models actually need to be useful.

hackernews · AnodicElegy · Aug 15, 19:12 · Discussion

「Background」 Drug discovery is the long, costly process of identifying and validating molecules that could become approved medicines, traditionally involving years of lab experimentation and clinical trials with high failure rates. Over the past decade, AI and machine learning have been heavily promoted as tools to accelerate this pipeline, from predicting molecular structures to designing candidate compounds, attracting significant investment and hype. This piece is a commentary by veteran chemistry writer Derek Lowe responding to a Nature perspective article that assesses, with a decade of hindsight, how much clinically relevant impact AI has actually delivered in drug discovery.

「Impact」 Practitioners like structural biologists report AI tools primarily accelerate tasks they could already do, such as scripting, debugging, and literature review, rather than enabling entirely new capabilities, suggesting near-term gains will be efficiency-focused rather than paradigm-shifting for professional drug discovery pipelines.

「Community Discussion」 Commenters largely agree that AI's value in professional drug discovery is incremental rather than transformative, with a structural biologist noting it speeds up familiar tasks (scripting, debugging, literature checks) without unlocking new capabilities, while others point out a coordination problem where everyone wants better underlying data but no one wants to be the one to generate it. One commenter argued AI's more visible impact may be at the grassroots level, empowering non-experts to build tools outside traditional benchmarks, though this claim remains anecdotal.

Tags: #AI in science, #drug discovery, #machine learning applications, #biotech, #critical analysis

Run health